Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$6.87 -0.00%

-$0.00 today

Market cap
$865.72M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 3.97M

Average 2.58M

VSTM Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Verastem, Inc.NASDAQ: VSTM

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns positive

Q1 FY2026 other income / expenses was $8.31M, compared with -$7.93M a year earlier. Trailing-twelve-month other income / expenses was -$23.11M.

Context

  • Other income / expenses amounted to 127.3% of revenue in FY2025, down 27.7 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near $8.31M or moves back toward the trailing-twelve-month quarterly average of -$5.78M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.31M-2.9% QoQ
Last fiscal yearDec 2025
-$39.34M-153.9% YoY
LTMMar 2026
-$23.11M-31.1% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+204.8%——
1 year-153.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(39.34M) USD
Year-over-year change
-153.9%

Other Income / Expenses vs competitors

How VSTM compares with its peers on the latest reported figures

  • VSTM's LTM Mar 2026 other income / expenses of -$23.11M is the lowest of the 11 companies compared; the peer median is $5.89M.
  • Its year-over-year change of -31.1% is the 6th highest of 10, against a peer median of -24.2%.
  • Other income / expenses amounts to 46.6% of revenue for VSTM, versus a peer median of 33.5%.
VSTM Competitors Peer median
Other Income / Expenses for VSTM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$14.77M +85.5%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$14.69M +6.7%+72.3%—
ANLAdlai Nortye Ltd.LTM Jun 2024$11.25M —-72.8%173.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$10.16M -24.2%—29.2%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$6.34M -47.8%-14.5%37.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$5.44M -67.9%-1.8%19.3%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$5.09M -46.1%+60.9%—
IMRXImmuneering CorporationLTM Mar 2026$4.79M +95.0%+39.6%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.67M -17.9%+37.4%507.8%
NUVBNuvation Bio Inc.LTM Jun 2026-$12.2M -156.1%-18.4%7.2%
VSTMVerastem, Inc.LTM Mar 2026-$23.11M -31.1%—46.6%
Peer median (excluding VSTM) $5.89M-24.2%+17.8%33.5%

Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.05M2.6M010M30.91M
Cost of Revenue00005.3M
Gross Profit2.05M2.6M010M25.62M
Gross Margin100.0%100.0%—100.0%82.9%
Research & Development39.35M50.56M61.36M81.33M114.6M
Selling, General & Admin24.12M24.98M30.73M43.62M81.15M
Operating Expenses63.46M75.53M92.08M124.96M195.75M
Depreciation & Amortization72K118K62K26K728K
EBITDA(61.16M)(71.56M)(83.17M)(125.86M)(207.61M)
EBITDA Margin-2978.9%-2756.4%—-1258.6%-671.6%
Operating Income(61.41M)(72.94M)(92.08M)(114.96M)(170.13M)
Operating Margin-2991.2%-2809.6%—-1149.6%-550.3%
Interest Income181K1.22M6.21M4.15M4.07M
Interest Expense9.97M2.14M4.14M4.56M1.14M
Other Income / Expenses(9.79M)(875K)4.72M(15.5M)(39.34M)
Income Before Tax(71.2M)(73.81M)(87.37M)(130.45M)(209.47M)
Pre-Tax Margin-3468.1%-2843.3%—-1304.5%-677.6%
Income Tax Expense000185K0
Net Income(71.2M)(73.81M)(87.37M)(130.64M)(209.47M)
Net Margin-3468.1%-2843.3%—-1306.4%-677.6%
EPS (Basic)(4.92)(4.57)(3.96)(3.66)(3.02)
EPS (Diluted)(4.92)(4.57)(3.96)(3.66)(3.02)
Weighted Avg Shares14.53M16.14M22.05M35.71M69.31M
Weighted Avg Shares (Diluted)14.53M16.14M22.05M35.71M69.31M

Verastem, Inc.

NASDAQ:VSTM

Intrinsic Alpha fair value

Locked

Current Price

$6.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.